[HTML] sciencedirect.com

[HTML][HTML] Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients …

G Chen, J Feng, C Zhou, YL Wu, XQ Liu, C Wang… - Annals of …, 2013 - Elsevier
Background The OPTIMAL study found that erlotinib improved progression-free survival
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …
被引用次数：149 相关文章

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with …

G Chen, J Feng, C Zhou, YL Wu, XQ Liu… - Annals of …, 2013 - annalsofoncology.org
Background The OPTIMAL study found that erlotinib improved progression-free survival
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …
[PDF] researchgate.net

[PDF][PDF] Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with …

G Chen, J Feng, C Zhou, YL Wu, XQ Liu, C Wang… - 2013 - researchgate.net
Background: The OPTIMAL study found that erlotinib improved progression-free survival
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …

[引用][C] Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with …

G CHEN, J FENG, S LU, L ZHANG, CP HU… - Annals of …, 2013 - pascal-francis.inist.fr
Author CHEN, G 1; FENG, J 2; LU, S 9; ZHANG, L 10; HU, C.-P 11; HU, C 12; LUO, Y 13;
CHEN, L 14; YE, M 15; HUANG, J 16; ZHI, X 17; ZHANG, Y 18; ZHOU, C 3; XIU, Q 19; MA, J …

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with …

G Chen, J Feng, C Zhou, YL Wu, XQ Liu… - Annals of Oncology …, 2013 - europepmc.org
Background The OPTIMAL study found that erlotinib improved progression-free survival
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …

[引用][C] Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with …

G Chen, J Feng, C Zhou, YL Wu, XQ Liu, C Wang… - Annals of …, 2013 - cir.nii.ac.jp
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label
study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive …

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with …

G Chen, J Feng, C Zhou, YL Wu… - Annals of oncology …, 2013 - pubmed.ncbi.nlm.nih.gov
Background The OPTIMAL study found that erlotinib improved progression-free survival
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …

[引用][C] Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with …

G CHEN, J FENG, C ZHOU, YL WU… - Annals of …, 2013 - Oxford University Press

[引用][C] Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with …

G Chen, J Feng, C Zhou, YL Wu, XQ Liu… - Annals of …, 2013 - Oxford University Press